Search Results

[20-June-2024] KAN-003 seeks to improve outcomes for patients with ICI-naive cancers and is undergoing preclinical studies in collaboration with the MD Anderson Cancer Center. PRINCETON, N.J. , June 20, 2024 /PRNewswire/ -- Kanvas Biosciences , a full-stack spatial biology company, today introduced its newest drug candidate in its Immuno-oncology Program: KAN-003. The Kanvas platform

Kanvas Biosciences, a full-stack spatial biology company, announced it has raised $12.5 million in additional funding co-led by existing investors DCVC and Lions Capital LLC, and participation from FemHealth Ventures, Germin8, Ki Tua Fund, and Pangaea Ventures as well as existing investors.

Kanvas Biosciences today announced it acquired two active therapeutics programs, a microbial library, and intellectual property from Federation Bio, a manufacturer of live biotherapeutics products (LBPs).

Kanvas Biosciences, the leader in microbiome mapping technology, announced today a $12M Pre-Series A funding round.

Staff cuts will leave IGM Biosciences with 37 employees. The company is also halting development of two bispecific antibody T cell engagers for autoimmune diseases.